JP5604673B2 - 中枢神経系の疲労回復又は疲労予防のための組成物 - Google Patents
中枢神経系の疲労回復又は疲労予防のための組成物 Download PDFInfo
- Publication number
- JP5604673B2 JP5604673B2 JP2007500397A JP2007500397A JP5604673B2 JP 5604673 B2 JP5604673 B2 JP 5604673B2 JP 2007500397 A JP2007500397 A JP 2007500397A JP 2007500397 A JP2007500397 A JP 2007500397A JP 5604673 B2 JP5604673 B2 JP 5604673B2
- Authority
- JP
- Japan
- Prior art keywords
- fatigue
- bcaa
- amino acids
- composition
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 16
- 210000003169 central nervous system Anatomy 0.000 title claims description 11
- 238000011084 recovery Methods 0.000 title description 11
- 230000002265 prevention Effects 0.000 title description 9
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 25
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 19
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 17
- 229930182817 methionine Natural products 0.000 claims description 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 6
- 206010016256 fatigue Diseases 0.000 description 51
- 229940024606 amino acid Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 229960004452 methionine Drugs 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 16
- 229960004441 tyrosine Drugs 0.000 description 16
- 229960005190 phenylalanine Drugs 0.000 description 15
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000002996 emotional effect Effects 0.000 description 10
- 229960004799 tryptophan Drugs 0.000 description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- MPUVBVXDFRDIPT-UHFFFAOYSA-N 2-Amino-2-norbornanecarboxylic acid Chemical compound C1CC2C(N)(C(O)=O)CC1C2 MPUVBVXDFRDIPT-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229960002743 glutamine Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- 229930195722 L-methionine Natural products 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 235000019454 L-leucine Nutrition 0.000 description 3
- 239000004395 L-leucine Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- -1 BCAA and tyrosine Chemical class 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
健康な20〜21歳の男女各4名ずつに、被験飲料を飲んでもらった後に、多面的感情状態尺度による検査ならびに気分プロフィール検査(日本語版POMS)を実施した。飲用してから30分間は、飲食や考え込むようなこと、過激な運動及び喫煙は控えるように被験者に促した後、待機させた。その後、内田クレペリン検査を前半15分、3分休憩、後半15分の工程で行い、脳疲労(急性的な脳疲労)を課した。その直後に、多面的感情尺度項目(表2)に実験直後の感情状態を記入させ、その後POMS検査により過去1週間の感情状態(慢性的な脳疲労感)を記入させた。実験は1回につき、ドリンク飲用後の休憩30分、内田クレペリン検査に33分、多面的感情状態尺度項目及びPOMSの記入に10分の計80分弱を要した。なお、試験に先立ち、本試験をする目的、方法等の注意事項を説明した上で、自由意思に基づく文書による同意を得た。
市販のオレンジジュース(サントリー(株)社製「なっちゃんオレンジ」:オレンジ、レモン果汁、果糖、香料、酸味料、ビタミンC含有。なお、100ml当たりの栄養成分表示はエネルギー36kcal、タンパク質0.2g、脂質0g、炭水化物8.7g、ナトリウム0mg、ショ糖1.0gである。)200mlに、BCAA、チロシン、メチオニン、フェニルアラニン、グルタミンをそれぞれ次の表2に示す量で添加した。このときのBCAAには、3種の分岐鎖アミノ酸を各1gずつ用いた。
試験は1回200mlの飲料を飲むこととし、表2に示した実験群1〜4については各2回、実験群5及び6は各1回の計10回の実験(実験順序は次のとおり:実験群1→実験群2→実験群3→実験群4→実験群5→実験群1→実験群2→実験群3→実験群4→実験群6)を行った。
多面的感情状態尺度検査は、表3に示す結果集計用多面的感情状態尺度項目(寺崎正治ら、The Japanese Journal of Psychology,1992,Vol.62.No6,350-356)について、感じている:3点、少し感じている:2点、あまり感じていない1点:全く感じていない0点として、各項目ごとに点数を付けてもらった。そして、その後、脳疲労(急性疲労:急激に疲れた)に結び付いていると考えられる倦怠項目として、No3、11、26、36、42、48、54、64、67、80の項目を選び出し、被験者のスコアをそれぞれ算出した。多面的感情状態尺度検査は回答時点における評価を回答するものであり、選び出した項目に対する回答は急性疲労を評価していることになる。なお、実際の検査に際しては、表3の項目をNo.1からNo.87まで昇順に並び替えて実施した。
POMSは、日本版POMS(横山和仁ら、日本語版POMSNo.851,2002、金子書房)に記載された65項目の評価項目について、まったくなかった(スコア0)から非常に多くあった(スコア4)の5段階で評点を付けてもらった。そして、POMS記載の評価に従い、意欲・活力減退を示すF項目(疲れた、物事に気乗りがしない、ぐったりする、へとへとだ、だるい、うんざりだ、ひどくくたびれた)についてのスコアを求めた。POMSは多面的感情状態尺度検査と異なり、検査1週間前から回答時点までの期間における評価を回答するものであり、選び出した項目に対する回答は慢性疲労を評価していることになる。
表4及び表5に多面的感情状態尺度検査による試験結果を、表6にPOMS検査による試験結果を示した。なお、有効率は試験群1(コントロール群)に対してスコアが減った被験者の人数でもって表した。
Claims (2)
- 有効成分として、フェニルアラニンとメチオニン及び分岐鎖アミノ酸を含有し、他のアミノ酸を含有しない中枢神経系の疲労回復又は予防のための組成物。
- 有効成分として、さらにチロシンを含む請求項1に記載の中枢神経系の中枢神経系の疲労回復又は予防のための組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2005/001357 WO2006080086A1 (ja) | 2005-01-31 | 2005-01-31 | 中枢神経系の疲労回復又は疲労予防のための組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006080086A1 JPWO2006080086A1 (ja) | 2008-06-19 |
JP5604673B2 true JP5604673B2 (ja) | 2014-10-15 |
Family
ID=36740121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007500397A Active JP5604673B2 (ja) | 2005-01-31 | 2005-01-31 | 中枢神経系の疲労回復又は疲労予防のための組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080114067A1 (ja) |
JP (1) | JP5604673B2 (ja) |
WO (1) | WO2006080086A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041647A1 (ja) * | 2008-10-06 | 2010-04-15 | 明治乳業株式会社 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
JP5668271B2 (ja) * | 2008-12-25 | 2015-02-12 | ユーハ味覚糖株式会社 | シスチン−アミノ酸複合体及びその製造方法 |
US10369185B2 (en) | 2014-05-23 | 2019-08-06 | Kyowa Hakko Bio Co., Ltd. | Methods and compositions for enhancement of ability to concentrate |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
JP7266581B2 (ja) | 2017-08-14 | 2023-04-28 | アクセラ・ヘルス・インコーポレイテッド | 肝疾患の治療のためのアミノ酸組成物 |
JP2019058140A (ja) * | 2017-09-27 | 2019-04-18 | 味の素株式会社 | 栄養組成物 |
US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
JP7275499B2 (ja) | 2018-08-27 | 2023-05-18 | 味の素株式会社 | 脳機能改善用組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60202814A (ja) * | 1983-11-30 | 1985-10-14 | ブ−リンガ− ビオケミ−ア ロビンソチエタ ペル アツィオーニ | 人間の第4期睡眠増強剤 |
JPH09249556A (ja) * | 1996-01-09 | 1997-09-22 | Rikagaku Kenkyusho | アミノ酸組成物 |
WO2002034257A1 (fr) * | 2000-10-27 | 2002-05-02 | Meiji Dairies Corporation | Agents de recuperation ou de prevention de la fatigue dans le systeme nerveux central et aliments de recuperation ou de prevention associes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2947044B2 (ja) * | 1993-01-27 | 1999-09-13 | 味の素株式会社 | 免疫不全症候群治療の補助療法剤 |
EP0873754B1 (en) * | 1996-01-09 | 2003-07-30 | Riken | Amino acid compositions |
US6960358B2 (en) * | 2001-01-12 | 2005-11-01 | Crippen Raymond K | Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages |
US8338141B2 (en) * | 2003-07-08 | 2012-12-25 | Novus International, Inc. | Methionine recovery processes |
CA2577963C (en) * | 2004-08-25 | 2015-10-06 | Mtor Formulations Ltd. | Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle |
-
2005
- 2005-01-31 JP JP2007500397A patent/JP5604673B2/ja active Active
- 2005-01-31 US US11/883,173 patent/US20080114067A1/en not_active Abandoned
- 2005-01-31 WO PCT/JP2005/001357 patent/WO2006080086A1/ja not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60202814A (ja) * | 1983-11-30 | 1985-10-14 | ブ−リンガ− ビオケミ−ア ロビンソチエタ ペル アツィオーニ | 人間の第4期睡眠増強剤 |
JPH09249556A (ja) * | 1996-01-09 | 1997-09-22 | Rikagaku Kenkyusho | アミノ酸組成物 |
WO2002034257A1 (fr) * | 2000-10-27 | 2002-05-02 | Meiji Dairies Corporation | Agents de recuperation ou de prevention de la fatigue dans le systeme nerveux central et aliments de recuperation ou de prevention associes |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006080086A1 (ja) | 2008-06-19 |
US20080114067A1 (en) | 2008-05-15 |
WO2006080086A1 (ja) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200347413A1 (en) | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy | |
JP5604673B2 (ja) | 中枢神経系の疲労回復又は疲労予防のための組成物 | |
AU2020286177A1 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
JP5798648B2 (ja) | アミノ酸組成物を含有する疲労防止剤 | |
TWI583390B (zh) | 富含鞣花單寧之萃取物組成物 | |
JP6528800B2 (ja) | アミノ酸組成物 | |
JP6574809B2 (ja) | 慢性疲労の治療用の組成物および方法 | |
JP2022064912A (ja) | 哺乳動物において筋タンパク質合成および/または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 | |
JPWO2002034257A1 (ja) | 中枢神経系の疲労回復又は予防剤及び疲労回復又は予防のための食品 | |
US20150250761A1 (en) | Compositions and methods for treatment of chronic fatigue | |
US20150238518A1 (en) | Compositions and methods for treatment of neuropsychological deficits | |
EP3738590A1 (en) | Dietary supplement comprising amino acids for the treatment of sarcopenia | |
US8435963B2 (en) | Weight loss compositions and uses thereof | |
JP2015535241A (ja) | 脳機能低下の予防または改善剤 | |
TWI413519B (zh) | Bleaching acid or a pharmaceutically acceptable salt thereof as a prophylactic antihypertensive agent | |
US20230129451A1 (en) | Amino acid compositions and methods of manufacturing the compositions | |
US20140271908A1 (en) | Dietary supplements and methods for preventing and treating migraines | |
JP2017070271A (ja) | 食品またはサプリメント。 | |
ES2425045T3 (es) | Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa | |
JP6170166B2 (ja) | 脳機能低下の予防または改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120731 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140730 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5604673 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |